INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 417m ago
HOUSE PTR17m ago
SEC 13F17m ago
ROBINHOOD CHAIN17m ago
SEC FORM 4/Disposition to issuerVerified data

Bender Jeremy reported DAWN

Director, CHIEF EXECUTIVE OFFICER · Day One Biopharmaceuticals, Inc. · Day One Biopharmaceuticals, Inc. — Stock Option (right to buy Common Stock)

Side
D
Value
—
Shares
1.46M
Price
—
Executed
Apr 23, 2026
Disclosed
Apr 23, 2026
Disclosure timeline0 days from execution to publication · legal deadline 2 business days
Apr 23 executedApr 23, 2026 disclosed

DAWN · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Disposition to issuer — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 0 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · DAWN

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    DA
    Dubow AdamGen Counsel & Secretary
    DAWNDay One Biopharmaceuticals, Inc.
    Disposition to issuer
    		D—
    5,250 sh
    		Apr 23, 2026Apr 23, 2026
    traded Apr 23, 2026
    		+0dSEC FORM 4

    Evidence

    9
    DA
    Dubow AdamGen Counsel & Secretary
    DAWNDay One Biopharmaceuticals, Inc.
    Disposition to issuer
    		D—
    25.8K sh
    		Apr 23, 2026Apr 23, 2026
    traded Apr 23, 2026
    		+0dSEC FORM 4

    Evidence

    9
    JA
    Josey John A.Director
    DAWNDay One Biopharmaceuticals, Inc.
    Disposition to issuer
    		D—
    15.0K sh
    		Apr 23, 2026Apr 23, 2026
    traded Apr 23, 2026
    		+0dSEC FORM 4

    Evidence

    9
    DA
    Dubow AdamGen Counsel & Secretary
    DAWNDay One Biopharmaceuticals, Inc.
    Disposition to issuer
    		D—
    105.0K sh
    		Apr 23, 2026Apr 23, 2026
    traded Apr 23, 2026
    		+0dSEC FORM 4

    Evidence

    9
    ML
    Merendino LaurenChief Commercial Officer
    DAWNDay One Biopharmaceuticals, Inc.
    Disposition to issuer
    		D—
    69.4K sh
    		Apr 23, 2026Apr 23, 2026
    traded Apr 23, 2026
    		+0dSEC FORM 4

    Evidence

    9
    ML
    Merendino LaurenChief Commercial Officer
    DAWNDay One Biopharmaceuticals, Inc.
    Disposition to issuer
    		D—
    40.6K sh
    		Apr 23, 2026Apr 23, 2026
    traded Apr 23, 2026
    		+0dSEC FORM 4

    Evidence

    9
    JA
    Josey John A.Director
    DAWNDay One Biopharmaceuticals, Inc.
    Disposition to issuer
    		D—
    32.3K sh
    		Apr 23, 2026Apr 23, 2026
    traded Apr 23, 2026
    		+0dSEC FORM 4

    Evidence

    9
    JA
    Josey John A.Director
    DAWNDay One Biopharmaceuticals, Inc.
    Disposition to issuer
    		D—
    22.5K sh
    		Apr 23, 2026Apr 23, 2026
    traded Apr 23, 2026
    		+0dSEC FORM 4

    Evidence

    9
    YN
    York Charles N IICOO and CFO
    DAWNDay One Biopharmaceuticals, Inc.
    Disposition to issuer
    		D—
    162.0K sh
    		Apr 23, 2026Apr 23, 2026
    traded Apr 23, 2026
    		+0dSEC FORM 4

    Evidence

    9
    DA
    Dubow AdamGen Counsel & Secretary
    DAWNDay One Biopharmaceuticals, Inc.
    Disposition to issuer
    		D—
    309.0K sh
    		Apr 23, 2026Apr 23, 2026
    traded Apr 23, 2026
    		+0dSEC FORM 4

    Evidence

    9
    BJ
    Bender JeremyDirector, CHIEF EXECUTIVE OFFICER
    DAWNDay One Biopharmaceuticals, Inc.
    Disposition to issuer
    		D—
    81.8K sh
    		Apr 23, 2026Apr 23, 2026
    traded Apr 23, 2026
    		+0dSEC FORM 4

    Evidence

    9
    BJ
    Bender JeremyDirector, CHIEF EXECUTIVE OFFICER
    DAWNDay One Biopharmaceuticals, Inc.
    Disposition to issuer
    		D—
    286.0K sh
    		Apr 23, 2026Apr 23, 2026
    traded Apr 23, 2026
    		+0dSEC FORM 4

    Evidence

    9
    ML
    Merendino LaurenChief Commercial Officer
    DAWNDay One Biopharmaceuticals, Inc.
    Disposition to issuer
    		D—
    60.2K sh
    		Apr 23, 2026Apr 23, 2026
    traded Apr 23, 2026
    		+0dSEC FORM 4

    Evidence

    9
    ML
    Merendino LaurenChief Commercial Officer
    DAWNDay One Biopharmaceuticals, Inc.
    Disposition to issuer
    		D—
    25.8K sh
    		Apr 23, 2026Apr 23, 2026
    traded Apr 23, 2026
    		+0dSEC FORM 4

    Evidence

    9
    JA
    Josey John A.Director
    DAWNDay One Biopharmaceuticals, Inc.
    Disposition to issuer
    		D—
    1,181 sh
    		Apr 23, 2026Apr 23, 2026
    traded Apr 23, 2026
    		+0dSEC FORM 4

    Evidence

    9
    JA
    Josey John A.Director
    DAWNDay One Biopharmaceuticals, Inc.
    Disposition to issuer
    		D—
    37.5K sh
    		Apr 23, 2026Apr 23, 2026
    traded Apr 23, 2026
    		+0dSEC FORM 4

    Evidence

    9
    DA
    Dubow AdamGen Counsel & Secretary
    DAWNDay One Biopharmaceuticals, Inc.
    Disposition to issuer
    		D—
    90.0K sh
    		Apr 23, 2026Apr 23, 2026
    traded Apr 23, 2026
    		+0dSEC FORM 4

    Evidence

    9
    ML
    Merendino LaurenChief Commercial Officer
    DAWNDay One Biopharmaceuticals, Inc.
    Disposition to issuer
    		D—
    19.0K sh
    		Apr 23, 2026Apr 23, 2026
    traded Apr 23, 2026
    		+0dSEC FORM 4

    Evidence

    9
    DA
    Dubow AdamGen Counsel & Secretary
    DAWNDay One Biopharmaceuticals, Inc.
    Disposition to issuer
    		D—
    8,889 sh
    		Apr 23, 2026Apr 23, 2026
    traded Apr 23, 2026
    		+0dSEC FORM 4

    Evidence

    9
    GW
    Grossman WilliamDirector
    DAWNDay One Biopharmaceuticals, Inc.
    Disposition to issuer
    		D—
    32.3K sh
    		Apr 23, 2026Apr 23, 2026
    traded Apr 23, 2026
    		+0dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001863107-26-000005
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Apr 23, 2026
    Published
    Apr 23, 2026
    Ingested by INSIDER
    Nov 5, 04:03 UTC
    Last re-read
    Nov 5, 04:03 UTC

    Extracted facts

    Filer
    Bender Jeremy
    Role
    Director, CHIEF EXECUTIVE OFFICER
    Transaction
    Disposition to issuerAs filed: “D”
    Asset
    Day One Biopharmaceuticals, Inc. — Stock Option (right to buy Common Stock)
    Ticker
    DAWN
    Shares
    1.46M
    Execution date (reported)
    Apr 23, 2026
    Owned after transaction
    0 shares
    Days from execution to publication
    0

    What this establishes

    Bender Jeremy filed this Form 4 reporting a disposition to issuer of DAWN on Apr 23, 2026. It became public on Apr 23, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director, CHIEF EXECUTIVE OFFICER
    Bender Jeremycik:0001863107
    Issuer
    Day One Biopharmaceuticals, Inc.cik:0001845337

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.

    Source error

    Price history for DAWN is unavailable.

    An error occurred in the Server Components render. The specific message is omitted in production builds to avoid leaking sensitive details. A digest property is included on this error instance which may provide additional details about the nature of the error.